Silvia Delgado

Silvia Delgado, M.D.

Clinical Assistant Professor

Department: MD-PEDS-PULMONARY
Business Phone: (352) 294-5252
Business Email: silviadelgado@ufl.edu

About Silvia Delgado

Silvia Delgado, MD, is the Director of the Pediatric Cystic Fibrosis Center at the University of Florida as well as the Newborn Screen Cystic Fibrosis Center Director. She is a Clinical Assistant Professor of Pediatrics in the Pediatric Pulmonary Division at the University of Florida.

Dr. Delgado is board certified in General Pediatrics and Pediatric Pulmonary Medicine.

Dr. Delgado obtained her medical degree at Universidad Dr. José Matías Delgado Escuela de Medicina in El Salvador. She completed postgraduate training in Pediatrics in State University of New York in Brooklyn, having also completed her Pediatric Pulmonary Fellowship at Children’s National Health System in Washington D.C.

Before joining the faculty at the University of Florida, Dr. Delgado was an Assistant Professor of Pediatrics in the University of Maryland Medical Center in Baltimore, Md.

Dr. Delgado evaluates and treats children with a wide range of respiratory disorders, such as asthma, chronic aspiration, tracheomalacia, bronchomalacia, congenital lung abnormalities, etc.

Her areas of interest include cystic fibrosis and chronic lung disease of prematurity, as well as quality improvement.

Dr. Delgado has a personal interest in improving care of cystic fibrosis patients in developing countries.

Teaching Profile

Courses Taught
2018
MDT7400 Elect Top/Pediatrics

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Pulmonary
Areas of Interest
  • Asthma
  • Cystic fibrosis
  • Lung disease

Grants

Jul 2022 ACTIVE
109 Cystic Fibrosis Foundation Care Center and Patient Registry.
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Apr 2022 ACTIVE
Therapeutics Development Center Award
Role: Co-Investigator
Funding: CYSTIC FIBROSIS FOU
Jul 2021 – Jun 2022
109 Cystic Fibrosis Foundation Care Center and Patient Registry
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Jan 2021 ACTIVE
Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis
Role: Principal Investigator
Funding: SEATTLE CHILDRENS HOSPITAL via CYSTIC FIBROSIS FOU
Jul 2020 – Jun 2021
109 Cystic Fibrosis Foundation Care Center and Patient Registry
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Apr 2020 – Mar 2022
Therapeutics Development Center
Role: Co-Investigator
Funding: CYSTIC FIBROSIS FOU
Jan 2020 ACTIVE
A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)
Role: Principal Investigator
Funding: SEATTLE CHILDRENS HOSPITAL via CYSTIC FIBROSIS FOU
Jul 2019 – Jun 2020
109 Cystic Fibrosis Foundation Care Center and Patient Registry
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Jul 2019 – Jun 2020
First Year Clinical Fellowship
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Apr 2019 – Mar 2022
Implementation of Outpatient Clinical Pharmacy Services: Award for A Pharmacist and/or Pharmacy Technician
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Jul 2018 – Jun 2019
109 Cystic Fibrosis Foundation Care Center and Patient Registry
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Sep 2017 – Mar 2022
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AeroVanc for the Treatment of Persistent Methicillin-Resistant Stphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
Role: Principal Investigator
Funding: SAVARA PHARMACEUTICALS
Jun 2017 – Nov 2018
Fundamentals Learning and Leadership Collaborative 3
Role: Principal Investigator
Funding: DARTMOUTH INST MICROSYSTEM ACAD via CYSTIC FIBROSIS FOU
Mar 2017 – Feb 2019
Telemedicine Genetic Counseling in the Provision of CF Newborn Screening
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Nov 2016 – Apr 2020
Implementation of Outpatient Clinical Pharmacy Services
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Aug 2016 – Aug 2021
Psychometric Evaluation of the Gastrointestinal (GI) Symptom Tracker in Patients With Cystic Fibrosis
Role: Principal Investigator
Funding: RESEARCH TRIANGLE INST
Aug 2016 – Aug 2021
Psychometric Evaluation of the Gastrointestinal (GI) Symptom Tracker in Patients With Cystic Fibrosis
Role: Principal Investigator
Funding: RESEARCH TRIANGLE INST
Jul 2016 ACTIVE
CMS Newborn Screening – COQWX
Role: Principal Investigator
Funding: FL DEPT OF HLTH CHILDRENS MED SERVS
Jul 2016 – Jun 2019
109 Cystic Fibrosis Foundation Care Center and Patient Registry
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Jan 2016 – Dec 2019
implementation of the depression and anxiety guidelines: Award for a mental health coordinator
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Jan 2015 – Mar 2020
Therapeutics Development Center Award
Role: Project Manager
Funding: CYSTIC FIBROSIS FOU THERAPEUTICS
Aug 2013 – Dec 2016
Telemedicine Genetic Counseling in the provision of CF Newborn Screening
Role: Principal Investigator
Funding: CYSTIC FIBROSIS FOU
Jul 2012 – Jul 2021
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: Protocol CFFC-OB-11
Role: Principal Investigator
Funding: SEATTLE CHILDRENS HOSPITAL via CYSTIC FIBROSIS FOU THERAPEUTICS
Jul 2012 – Jul 2021
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: Protocol CFFC-OB-11
Role: Principal Investigator
Funding: SEATTLE CHILDRENS HOSPITAL via CYSTIC FIBROSIS FOU THERAPEUTICS

Contact Details

Phones:
Business:
(352) 294-5252
Emails:
Addresses:
Business Mailing:
PO Box 100296
GAINESVILLE FL 32610
Business Street:
HD-506
1600 SW ARCHER RD
Gainesville FL 32610